ID   KCC2A_HUMAN             Reviewed;         478 AA.
AC   Q9UQM7; Q9UL21; Q9Y2H4; Q9Y352;
DT   16-APR-2002, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   12-OCT-2022, entry version 204.
DE   RecName: Full=Calcium/calmodulin-dependent protein kinase type II subunit alpha;
DE            Short=CaM kinase II subunit alpha;
DE            Short=CaMK-II subunit alpha;
DE            EC=2.7.11.17 {ECO:0000269|PubMed:23805378};
GN   Name=CAMK2A; Synonyms=CAMKA, KIAA0968;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B).
RC   TISSUE=Brain;
RA   Li G.Y., Cooper N.G.F.;
RT   "Human calcium/calmodulin-dependent protein kinase II: cDNA cloning and
RT   gene analysis.";
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   FUNCTION.
RX   PubMed=11972023; DOI=10.1073/pnas.052159099;
RA   Nair J.S., DaFonseca C.J., Tjernberg A., Sun W., Darnell J.E. Jr.,
RA   Chait B.T., Zhang J.J.;
RT   "Requirement of Ca2+ and CaMKII for Stat1 Ser-727 phosphorylation in
RT   response to IFN-gamma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5971-5976(2002).
RN   [5]
RP   FUNCTION, ACTIVITY REGULATION, SUBUNIT, AND AUTOPHOSPHORYLATION.
RX   PubMed=14722083; DOI=10.1074/jbc.m313597200;
RA   Gaertner T.R., Kolodziej S.J., Wang D., Kobayashi R., Koomen J.M.,
RA   Stoops J.K., Waxham M.N.;
RT   "Comparative analyses of the three-dimensional structures and enzymatic
RT   properties of alpha, beta, gamma and delta isoforms of Ca2+-calmodulin-
RT   dependent protein kinase II.";
RL   J. Biol. Chem. 279:12484-12494(2004).
RN   [6]
RP   INTERACTION WITH MPDZ.
RX   PubMed=15312654; DOI=10.1016/j.neuron.2004.08.003;
RA   Krapivinsky G., Medina I., Krapivinsky L., Gapon S., Clapham D.E.;
RT   "SynGAP-MUPP1-CaMKII synaptic complexes regulate p38 MAP kinase activity
RT   and NMDA receptor-dependent synaptic AMPA receptor potentiation.";
RL   Neuron 43:563-574(2004).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=23805378; DOI=10.7554/elife.00518;
RA   Tao L., Xie Q., Ding Y.H., Li S.T., Peng S., Zhang Y.P., Tan D., Yuan Z.,
RA   Dong M.Q.;
RT   "CAMKII and Calcineurin regulate the lifespan of Caenorhabditis elegans
RT   through the FOXO transcription factor DAF-16.";
RL   Elife 2:E00518-E00518(2013).
RN   [8]
RP   FUNCTION, INTERACTION WITH CACNB2; GRIN2B; GRM5; LRRC7 AND SHANK3,
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANT MRD53 VAL-183.
RX   PubMed=28130356; DOI=10.1523/jneurosci.2068-16.2017;
RA   Stephenson J.R., Wang X., Perfitt T.L., Parrish W.P., Shonesy B.C.,
RA   Marks C.R., Mortlock D.P., Nakagawa T., Sutcliffe J.S., Colbran R.J.;
RT   "Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and
RT   Causes ASD-Related Behaviors.";
RL   J. Neurosci. 37:2216-2233(2017).
RN   [9]
RP   VARIANT MRD53 ALA-138.
RX   PubMed=25533962; DOI=10.1038/nature14135;
RG   Deciphering Developmental Disorders Study;
RT   "Large-scale discovery of novel genetic causes of developmental
RT   disorders.";
RL   Nature 519:223-228(2015).
RN   [10]
RP   INVOLVEMENT IN MRD53, VARIANTS MRD53 SER-98; ASP-109; VAL-112; VAL-183;
RP   LEU-212; LEU-235; ARG-282 AND PRO-286, CHARACTERIZATION OF VARIANTS MRD53
RP   ALA-98; ASP-109; ALA-138; VAL-183; LEU-212; LEU-235; ARG-282 AND PRO-286,
RP   FUNCTION, AND MUTAGENESIS OF LYS-42 AND THR-286.
RX   PubMed=29100089; DOI=10.1016/j.ajhg.2017.10.003;
RG   Undiagnosed Diseases Network;
RG   GEM HUGO;
RG   Deciphering Developmental Disorders Study;
RA   Kuery S., van Woerden G.M., Besnard T., Proietti Onori M., Latypova X.,
RA   Towne M.C., Cho M.T., Prescott T.E., Ploeg M.A., Sanders S.,
RA   Stessman H.A.F., Pujol A., Distel B., Robak L.A., Bernstein J.A.,
RA   Denomme-Pichon A.S., Lesca G., Sellars E.A., Berg J., Carre W., Busk O.L.,
RA   van Bon B.W.M., Waugh J.L., Deardorff M., Hoganson G.E., Bosanko K.B.,
RA   Johnson D.S., Dabir T., Holla O.L., Sarkar A., Tveten K., de Bellescize J.,
RA   Braathen G.J., Terhal P.A., Grange D.K., van Haeringen A., Lam C.,
RA   Mirzaa G., Burton J., Bhoj E.J., Douglas J., Santani A.B., Nesbitt A.I.,
RA   Helbig K.L., Andrews M.V., Begtrup A., Tang S., van Gassen K.L.I.,
RA   Juusola J., Foss K., Enns G.M., Moog U., Hinderhofer K., Paramasivam N.,
RA   Lincoln S., Kusako B.H., Lindenbaum P., Charpentier E., Nowak C.B.,
RA   Cherot E., Simonet T., Ruivenkamp C.A.L., Hahn S., Brownstein C.A., Xia F.,
RA   Schmitt S., Deb W., Bonneau D., Nizon M., Quinquis D., Chelly J.,
RA   Rudolf G., Sanlaville D., Parent P., Gilbert-Dussardier B., Toutain A.,
RA   Sutton V.R., Thies J., Peart-Vissers L.E.L.M., Boisseau P., Vincent M.,
RA   Grabrucker A.M., Dubourg C., Tan W.H., Verbeek N.E., Granzow M.,
RA   Santen G.W.E., Shendure J., Isidor B., Pasquier L., Redon R., Yang Y.,
RA   State M.W., Kleefstra T., Cogne B., Petrovski S., Retterer K.,
RA   Eichler E.E., Rosenfeld J.A., Agrawal P.B., Bezieau S., Odent S.,
RA   Elgersma Y., Mercier S.;
RT   "De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause
RT   Intellectual Disability.";
RL   Am. J. Hum. Genet. 101:768-788(2017).
RN   [11]
RP   INVOLVEMENT IN MRD53, VARIANTS MRD53 GLN-212 AND LEU-235, AND
RP   CHARACTERIZATION OF VARIANTS MRD53 GLN-212 AND LEU-235.
RX   PubMed=29560374; DOI=10.1002/acn3.528;
RA   Akita T., Aoto K., Kato M., Shiina M., Mutoh H., Nakashima M., Kuki I.,
RA   Okazaki S., Magara S., Shiihara T., Yokochi K., Aiba K., Tohyama J.,
RA   Ohba C., Miyatake S., Miyake N., Ogata K., Fukuda A., Matsumoto N.,
RA   Saitsu H.;
RT   "De novo variants in CAMK2A and CAMK2B cause neurodevelopmental
RT   disorders.";
RL   Ann. Clin. Transl. Neurol. 5:280-296(2018).
RN   [12]
RP   INVOLVEMENT IN MRT63, SUBUNIT, VARIANT MRT63 TYR-466, CHARACTERIZATION OF
RP   VARIANT MRT63 TYR-466, AND MUTAGENESIS OF 466-HIS--HIS-478.
RX   PubMed=29784083; DOI=10.7554/elife.32451;
RA   Chia P.H., Zhong F.L., Niwa S., Bonnard C., Utami K.H., Zeng R., Lee H.,
RA   Eskin A., Nelson S.F., Xie W.H., Al-Tawalbeh S., El-Khateeb M., Shboul M.,
RA   Pouladi M.A., Al-Raqad M., Reversade B.;
RT   "A homozygous loss-of-function CAMK2A mutation causes growth delay,
RT   frequent seizures and severe intellectual disability.";
RL   Elife 7:0-0(2018).
RN   [13]
RP   FUNCTION.
RX   PubMed=35568036; DOI=10.1016/j.cell.2022.04.028;
RA   Alphonse N., Wanford J.J., Voak A.A., Gay J., Venkhaya S., Burroughs O.,
RA   Mathew S., Lee T., Evans S.L., Zhao W., Frowde K., Alrehaili A.,
RA   Dickenson R.E., Munk M., Panina S., Mahmood I.F., Llorian M.,
RA   Stanifer M.L., Boulant S., Berchtold M.W., Bergeron J.R.C., Wack A.,
RA   Lesser C.F., Odendall C.;
RT   "A family of conserved bacterial virulence factors dampens interferon
RT   responses by blocking calcium signaling.";
RL   Cell 185:2354-2369(2022).
CC   -!- FUNCTION: Calcium/calmodulin-dependent protein kinase that functions
CC       autonomously after Ca(2+)/calmodulin-binding and autophosphorylation,
CC       and is involved in various processes, such as synaptic plasticity,
CC       neurotransmitter release and long-term potentiation (PubMed:14722083).
CC       Member of the NMDAR signaling complex in excitatory synapses, it
CC       regulates NMDAR-dependent potentiation of the AMPAR and therefore
CC       excitatory synaptic transmission (By similarity). Regulates dendritic
CC       spine development (PubMed:28130356). Also regulates the migration of
CC       developing neurons (PubMed:29100089). Phosphorylates the transcription
CC       factor FOXO3 to activate its transcriptional activity
CC       (PubMed:23805378). Phosphorylates the transcription factor ETS1 in
CC       response to calcium signaling, thereby decreasing ETS1 affinity for DNA
CC       (By similarity). In response to interferon-gamma (IFN-gamma)
CC       stimulation, catalyzes phosphorylation of STAT1, stimulating the JAK-
CC       STAT signaling pathway (PubMed:11972023). In response to interferon-
CC       beta (IFN-beta) stimulation, stimulates the JAK-STAT signaling pathway
CC       (PubMed:35568036). Acts as a negative regulator of 2-
CC       arachidonoylglycerol (2-AG)-mediated synaptic signaling via modulation
CC       of DAGLA activity (By similarity). {ECO:0000250|UniProtKB:P11275,
CC       ECO:0000250|UniProtKB:P11798, ECO:0000269|PubMed:11972023,
CC       ECO:0000269|PubMed:23805378, ECO:0000269|PubMed:28130356,
CC       ECO:0000269|PubMed:29100089}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17;
CC         Evidence={ECO:0000269|PubMed:23805378};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.17; Evidence={ECO:0000269|PubMed:23805378};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:23805378};
CC   -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of
CC       calmodulin results in conformational change that relieves intrasteric
CC       autoinhibition and allows autophosphorylation of Thr-286 which turns
CC       the kinase in a constitutively active form and confers to the kinase a
CC       Ca(2+)-independent activity. {ECO:0000269|PubMed:14722083}.
CC   -!- SUBUNIT: There are 4 genes encoding calcium/calmodulin-dependent
CC       protein kinase type II chains: CAMK2A, CAMK2B, CAMK2G and CAMK2D. The
CC       corresponding proteins assemble into homo- or heteromultimeric
CC       holoenzymes composed of 12 subunits with two hexameric rings stacked
CC       one on top of the other (PubMed:14722083, PubMed:29784083). Interacts
CC       with BAALC. Interacts with MPDZ. Interacts with SYN1. Interacts with
CC       CAMK2N2. Interacts with SYNGAP1. Interacts with SYNPO2 (By similarity).
CC       Interacts with SHANK3 (PubMed:28130356). Interacts with GRIN2B
CC       (PubMed:28130356). Interacts with CACNB2 (PubMed:28130356). Interacts
CC       with LRRC7 (PubMed:28130356). Interacts with GRM5 (PubMed:28130356).
CC       Interacts with DAGLA (via C-terminal); this interaction is enhanced by
CC       autophosphorylation of CAMK2A at Thr-286 (By similarity). Interacts
CC       with CAMK2N1; this interaction requires CAMK2A activation by Ca(2+) (By
CC       similarity). {ECO:0000250|UniProtKB:P11275,
CC       ECO:0000250|UniProtKB:P11798, ECO:0000269|PubMed:14722083,
CC       ECO:0000269|PubMed:28130356, ECO:0000269|PubMed:29784083}.
CC   -!- INTERACTION:
CC       Q9UQM7; P68133: ACTA1; NbExp=3; IntAct=EBI-1383687, EBI-367510;
CC       Q9UQM7; P31749: AKT1; NbExp=3; IntAct=EBI-1383687, EBI-296087;
CC       Q9UQM7; Q92870-2: APBB2; NbExp=3; IntAct=EBI-1383687, EBI-21535880;
CC       Q9UQM7; P05067: APP; NbExp=3; IntAct=EBI-1383687, EBI-77613;
CC       Q9UQM7; Q03989: ARID5A; NbExp=3; IntAct=EBI-1383687, EBI-948603;
CC       Q9UQM7; P13637: ATP1A3; NbExp=3; IntAct=EBI-1383687, EBI-948169;
CC       Q9UQM7; P23560-2: BDNF; NbExp=3; IntAct=EBI-1383687, EBI-12275524;
CC       Q9UQM7; Q6P1W5: C1orf94; NbExp=3; IntAct=EBI-1383687, EBI-946029;
CC       Q9UQM7; P62158: CALM3; NbExp=2; IntAct=EBI-1383687, EBI-397435;
CC       Q9UQM7; Q9UQM7: CAMK2A; NbExp=2; IntAct=EBI-1383687, EBI-1383687;
CC       Q9UQM7; Q13554: CAMK2B; NbExp=3; IntAct=EBI-1383687, EBI-1058722;
CC       Q9UQM7; Q13554-3: CAMK2B; NbExp=3; IntAct=EBI-1383687, EBI-11523526;
CC       Q9UQM7; Q13557: CAMK2D; NbExp=5; IntAct=EBI-1383687, EBI-351018;
CC       Q9UQM7; Q13557-8: CAMK2D; NbExp=3; IntAct=EBI-1383687, EBI-11534483;
CC       Q9UQM7; Q13555-5: CAMK2G; NbExp=3; IntAct=EBI-1383687, EBI-12020154;
CC       Q9UQM7; P35520: CBS; NbExp=3; IntAct=EBI-1383687, EBI-740135;
CC       Q9UQM7; Q16543: CDC37; NbExp=5; IntAct=EBI-1383687, EBI-295634;
CC       Q9UQM7; Q15038: DAZAP2; NbExp=3; IntAct=EBI-1383687, EBI-724310;
CC       Q9UQM7; Q92567-2: FAM168A; NbExp=3; IntAct=EBI-1383687, EBI-11978259;
CC       Q9UQM7; A1KXE4-2: FAM168B; NbExp=3; IntAct=EBI-1383687, EBI-12193763;
CC       Q9UQM7; P04406: GAPDH; NbExp=3; IntAct=EBI-1383687, EBI-354056;
CC       Q9UQM7; Q8IW92: GLB1L2; NbExp=3; IntAct=EBI-1383687, EBI-11954377;
CC       Q9UQM7; Q13224: GRIN2B; NbExp=3; IntAct=EBI-1383687, EBI-2256942;
CC       Q9UQM7; P07900: HSP90AA1; NbExp=5; IntAct=EBI-1383687, EBI-296047;
CC       Q9UQM7; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1383687, EBI-352572;
CC       Q9UQM7; O43820: HYAL3; NbExp=3; IntAct=EBI-1383687, EBI-3913399;
CC       Q9UQM7; O95678: KRT75; NbExp=3; IntAct=EBI-1383687, EBI-2949715;
CC       Q9UQM7; Q01546: KRT76; NbExp=3; IntAct=EBI-1383687, EBI-2952745;
CC       Q9UQM7; Q3LI76: KRTAP15-1; NbExp=3; IntAct=EBI-1383687, EBI-11992140;
CC       Q9UQM7; Q7Z4W3: KRTAP19-3; NbExp=3; IntAct=EBI-1383687, EBI-12020132;
CC       Q9UQM7; Q3LI72: KRTAP19-5; NbExp=3; IntAct=EBI-1383687, EBI-1048945;
CC       Q9UQM7; Q3SYF9: KRTAP19-7; NbExp=3; IntAct=EBI-1383687, EBI-10241353;
CC       Q9UQM7; A1A580: KRTAP23-1; NbExp=3; IntAct=EBI-1383687, EBI-10171734;
CC       Q9UQM7; Q3LI64: KRTAP6-1; NbExp=3; IntAct=EBI-1383687, EBI-12111050;
CC       Q9UQM7; Q3LI66: KRTAP6-2; NbExp=3; IntAct=EBI-1383687, EBI-11962084;
CC       Q9UQM7; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-1383687, EBI-10261141;
CC       Q9UQM7; Q14847-2: LASP1; NbExp=3; IntAct=EBI-1383687, EBI-9088686;
CC       Q9UQM7; Q96PV6: LENG8; NbExp=3; IntAct=EBI-1383687, EBI-739546;
CC       Q9UQM7; Q13387-4: MAPK8IP2; NbExp=3; IntAct=EBI-1383687, EBI-12345753;
CC       Q9UQM7; Q9Y3B7: MRPL11; NbExp=3; IntAct=EBI-1383687, EBI-5453723;
CC       Q9UQM7; P41271-2: NBL1; NbExp=3; IntAct=EBI-1383687, EBI-12135485;
CC       Q9UQM7; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-1383687, EBI-741158;
CC       Q9UQM7; P16284: PECAM1; NbExp=3; IntAct=EBI-1383687, EBI-716404;
CC       Q9UQM7; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-1383687, EBI-9090282;
CC       Q9UQM7; O14494: PLPP1; NbExp=3; IntAct=EBI-1383687, EBI-2865290;
CC       Q9UQM7; P00491: PNP; NbExp=3; IntAct=EBI-1383687, EBI-712238;
CC       Q9UQM7; P05771-2: PRKCB; NbExp=3; IntAct=EBI-1383687, EBI-5774511;
CC       Q9UQM7; P20339: RAB5A; NbExp=3; IntAct=EBI-1383687, EBI-399437;
CC       Q9UQM7; Q86SE5-3: RALYL; NbExp=3; IntAct=EBI-1383687, EBI-11526555;
CC       Q9UQM7; O43251-10: RBFOX2; NbExp=3; IntAct=EBI-1383687, EBI-11963050;
CC       Q9UQM7; A0AV96: RBM47; NbExp=3; IntAct=EBI-1383687, EBI-2823850;
CC       Q9UQM7; Q93062-3: RBPMS; NbExp=3; IntAct=EBI-1383687, EBI-740343;
CC       Q9UQM7; Q6ZRY4: RBPMS2; NbExp=3; IntAct=EBI-1383687, EBI-11987469;
CC       Q9UQM7; Q9BQY4: RHOXF2; NbExp=3; IntAct=EBI-1383687, EBI-372094;
CC       Q9UQM7; P04271: S100B; NbExp=3; IntAct=EBI-1383687, EBI-458391;
CC       Q9UQM7; P29353-7: SHC1; NbExp=3; IntAct=EBI-1383687, EBI-9691288;
CC       Q9UQM7; P84022: SMAD3; NbExp=3; IntAct=EBI-1383687, EBI-347161;
CC       Q9UQM7; P35711-4: SOX5; NbExp=3; IntAct=EBI-1383687, EBI-11954419;
CC       Q9UQM7; Q9UNE7: STUB1; NbExp=3; IntAct=EBI-1383687, EBI-357085;
CC       Q9UQM7; P51687: SUOX; NbExp=3; IntAct=EBI-1383687, EBI-3921347;
CC       Q9UQM7; Q9NYJ8: TAB2; NbExp=3; IntAct=EBI-1383687, EBI-358708;
CC       Q9UQM7; Q9Y4C2-2: TCAF1; NbExp=3; IntAct=EBI-1383687, EBI-11974855;
CC       Q9UQM7; Q96LM6: TEX37; NbExp=3; IntAct=EBI-1383687, EBI-743976;
CC       Q9UQM7; Q7Z6R9: TFAP2D; NbExp=3; IntAct=EBI-1383687, EBI-11952651;
CC       Q9UQM7; Q01085-2: TIAL1; NbExp=3; IntAct=EBI-1383687, EBI-11064654;
CC       Q9UQM7; O60784-2: TOM1; NbExp=3; IntAct=EBI-1383687, EBI-12117154;
CC       Q9UQM7; Q969E8: TSR2; NbExp=3; IntAct=EBI-1383687, EBI-746981;
CC       Q9UQM7; Q8N0Z6: TTC5; NbExp=3; IntAct=EBI-1383687, EBI-9526213;
CC       Q9UQM7; P61086: UBE2K; NbExp=3; IntAct=EBI-1383687, EBI-473850;
CC       Q9UQM7; P13051-2: UNG; NbExp=3; IntAct=EBI-1383687, EBI-25834258;
CC       Q9UQM7; Q9BVJ6: UTP14A; NbExp=3; IntAct=EBI-1383687, EBI-473284;
CC       Q9UQM7; P26640: VARS1; NbExp=3; IntAct=EBI-1383687, EBI-355765;
CC       Q9UQM7; P08670: VIM; NbExp=3; IntAct=EBI-1383687, EBI-353844;
CC       Q9UQM7; Q9UBQ0-2: VPS29; NbExp=3; IntAct=EBI-1383687, EBI-11141397;
CC       Q9UQM7; A0A0C4DGF1: ZBTB32; NbExp=3; IntAct=EBI-1383687, EBI-10188476;
CC   -!- SUBCELLULAR LOCATION: Synapse {ECO:0000250|UniProtKB:P11275}.
CC       Postsynaptic density {ECO:0000250|UniProtKB:P11275}. Cell projection,
CC       dendritic spine {ECO:0000269|PubMed:28130356}. Cell projection,
CC       dendrite {ECO:0000269|PubMed:28130356}. Note=Postsynaptic lipid rafts.
CC       {ECO:0000250|UniProtKB:P11275}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A;
CC         IsoId=Q9UQM7-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=Q9UQM7-2; Sequence=VSP_004766;
CC   -!- PTM: Autophosphorylation of Thr-286 following activation by
CC       Ca(2+)/calmodulin. Phosphorylation of Thr-286 locks the kinase into an
CC       activated state. {ECO:0000269|PubMed:14722083}.
CC   -!- PTM: Palmitoylated. Probably palmitoylated by ZDHHC3 and ZDHHC7.
CC       {ECO:0000250|UniProtKB:P11275}.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 53
CC       (MRD53) [MIM:617798]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period.
CC       {ECO:0000269|PubMed:25533962, ECO:0000269|PubMed:28130356,
CC       ECO:0000269|PubMed:29100089, ECO:0000269|PubMed:29560374}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal recessive 63
CC       (MRT63) [MIM:618095]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period. MRT63
CC       patients manifest global developmental delay, severe intellectual
CC       disability, and seizures. {ECO:0000269|PubMed:29784083}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. CaMK subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA76812.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF145710; AAD30558.1; -; mRNA.
DR   EMBL; AF145711; AAD30559.1; -; mRNA.
DR   EMBL; AB023185; BAA76812.1; ALT_INIT; mRNA.
DR   EMBL; AC011372; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS43386.1; -. [Q9UQM7-1]
DR   CCDS; CCDS43387.1; -. [Q9UQM7-2]
DR   RefSeq; NP_741960.1; NM_171825.2. [Q9UQM7-1]
DR   PDB; 2VZ6; X-ray; 2.30 A; A/B=13-302.
DR   PDB; 3SOA; X-ray; 3.55 A; A=1-474.
DR   PDB; 5IG3; X-ray; 2.75 A; A/B/C/D/E/F=345-475.
DR   PDB; 6OF8; X-ray; 2.10 A; A/B/C/D/E/F/G=345-475.
DR   PDB; 6VZK; X-ray; 2.55 A; A=7-274.
DR   PDB; 6W4O; EM; 4.80 A; A/B/C/D/E/F/G/I/J/K/L/M/O=7-478.
DR   PDB; 6W4P; EM; 6.60 A; A/B/C/D/E/F/G/H/I/J/K/L/M=7-478.
DR   PDB; 6X5G; X-ray; 1.85 A; A=7-274.
DR   PDB; 6X5Q; X-ray; 2.14 A; A=7-274.
DR   PDB; 7KL0; X-ray; 2.40 A; A/B=7-274.
DR   PDB; 7KL1; X-ray; 2.40 A; A/B=7-274.
DR   PDB; 7KL2; X-ray; 2.56 A; A=7-274.
DR   PDB; 7REC; X-ray; 2.20 A; A/B/C/D/E/F/G=345-475.
DR   PDB; 7UIQ; X-ray; 3.11 A; A/B=7-274.
DR   PDB; 7UIR; X-ray; 3.10 A; A/B=7-274.
DR   PDB; 7UIS; X-ray; 2.58 A; A=7-274.
DR   PDB; 7UJP; X-ray; 2.56 A; A/B=7-274.
DR   PDB; 7UJQ; X-ray; 2.25 A; A/B=7-274.
DR   PDB; 7UJR; X-ray; 1.95 A; A=7-274.
DR   PDB; 7UJS; X-ray; 2.75 A; A=7-274.
DR   PDB; 7UJT; X-ray; 2.10 A; A=7-274.
DR   PDBsum; 2VZ6; -.
DR   PDBsum; 3SOA; -.
DR   PDBsum; 5IG3; -.
DR   PDBsum; 6OF8; -.
DR   PDBsum; 6VZK; -.
DR   PDBsum; 6W4O; -.
DR   PDBsum; 6W4P; -.
DR   PDBsum; 6X5G; -.
DR   PDBsum; 6X5Q; -.
DR   PDBsum; 7KL0; -.
DR   PDBsum; 7KL1; -.
DR   PDBsum; 7KL2; -.
DR   PDBsum; 7REC; -.
DR   PDBsum; 7UIQ; -.
DR   PDBsum; 7UIR; -.
DR   PDBsum; 7UIS; -.
DR   PDBsum; 7UJP; -.
DR   PDBsum; 7UJQ; -.
DR   PDBsum; 7UJR; -.
DR   PDBsum; 7UJS; -.
DR   PDBsum; 7UJT; -.
DR   AlphaFoldDB; Q9UQM7; -.
DR   SMR; Q9UQM7; -.
DR   BioGRID; 107265; 198.
DR   CORUM; Q9UQM7; -.
DR   DIP; DIP-39705N; -.
DR   IntAct; Q9UQM7; 149.
DR   MINT; Q9UQM7; -.
DR   STRING; 9606.ENSP00000381412; -.
DR   BindingDB; Q9UQM7; -.
DR   ChEMBL; CHEMBL4147; -.
DR   DrugBank; DB07766; (2Z,3E)-2,3'-biindole-2',3(1H,1'H)-dione 3-{O-[(3R)-3,4-dihydroxybutyl]oxime}.
DR   DrugBank; DB04447; 1,4-Dithiothreitol.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB04119; Hexatantalum Dodecabromide.
DR   DrugCentral; Q9UQM7; -.
DR   GlyGen; Q9UQM7; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9UQM7; -.
DR   PhosphoSitePlus; Q9UQM7; -.
DR   BioMuta; CAMK2A; -.
DR   DMDM; 296434552; -.
DR   jPOST; Q9UQM7; -.
DR   MassIVE; Q9UQM7; -.
DR   MaxQB; Q9UQM7; -.
DR   PaxDb; Q9UQM7; -.
DR   PeptideAtlas; Q9UQM7; -.
DR   PRIDE; Q9UQM7; -.
DR   ProteomicsDB; 85559; -. [Q9UQM7-1]
DR   ProteomicsDB; 85560; -. [Q9UQM7-2]
DR   Antibodypedia; 3814; 902 antibodies from 51 providers.
DR   DNASU; 815; -.
DR   Ensembl; ENST00000348628.11; ENSP00000261793.8; ENSG00000070808.17. [Q9UQM7-1]
DR   Ensembl; ENST00000671881.1; ENSP00000500386.1; ENSG00000070808.17. [Q9UQM7-2]
DR   Ensembl; ENST00000672479.1; ENSP00000500642.1; ENSG00000070808.17. [Q9UQM7-1]
DR   Ensembl; ENST00000682786.1; ENSP00000507199.1; ENSG00000070808.17. [Q9UQM7-2]
DR   GeneID; 815; -.
DR   KEGG; hsa:815; -.
DR   MANE-Select; ENST00000671881.1; ENSP00000500386.1; NM_015981.4; NP_057065.2. [Q9UQM7-2]
DR   UCSC; uc003lrt.3; human. [Q9UQM7-1]
DR   CTD; 815; -.
DR   DisGeNET; 815; -.
DR   GeneCards; CAMK2A; -.
DR   HGNC; HGNC:1460; CAMK2A.
DR   HPA; ENSG00000070808; Tissue enriched (brain).
DR   MalaCards; CAMK2A; -.
DR   MIM; 114078; gene.
DR   MIM; 617798; phenotype.
DR   MIM; 618095; phenotype.
DR   neXtProt; NX_Q9UQM7; -.
DR   OpenTargets; ENSG00000070808; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   PharmGKB; PA90; -.
DR   VEuPathDB; HostDB:ENSG00000070808; -.
DR   eggNOG; KOG0033; Eukaryota.
DR   GeneTree; ENSGT00940000155150; -.
DR   HOGENOM; CLU_000288_71_0_1; -.
DR   InParanoid; Q9UQM7; -.
DR   OMA; SEETCIW; -.
DR   PhylomeDB; Q9UQM7; -.
DR   TreeFam; TF315229; -.
DR   BRENDA; 2.7.11.17; 2681.
DR   PathwayCommons; Q9UQM7; -.
DR   Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB.
DR   Reactome; R-HSA-3371571; HSF1-dependent transactivation.
DR   Reactome; R-HSA-399719; Trafficking of AMPA receptors.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-438066; Unblocking of NMDA receptors, glutamate binding and activation.
DR   Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity.
DR   Reactome; R-HSA-936837; Ion transport by P-type ATPases.
DR   Reactome; R-HSA-9609736; Assembly and cell surface presentation of NMDA receptors.
DR   Reactome; R-HSA-9617324; Negative regulation of NMDA receptor-mediated neuronal transmission.
DR   Reactome; R-HSA-9620244; Long-term potentiation.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   SignaLink; Q9UQM7; -.
DR   SIGNOR; Q9UQM7; -.
DR   BioGRID-ORCS; 815; 13 hits in 1103 CRISPR screens.
DR   ChiTaRS; CAMK2A; human.
DR   EvolutionaryTrace; Q9UQM7; -.
DR   GeneWiki; CAMK2A; -.
DR   GenomeRNAi; 815; -.
DR   Pharos; Q9UQM7; Tchem.
DR   PRO; PR:Q9UQM7; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q9UQM7; protein.
DR   Bgee; ENSG00000070808; Expressed in amygdala and 144 other tissues.
DR   ExpressionAtlas; Q9UQM7; baseline and differential.
DR   Genevisible; Q9UQM7; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0005954; C:calcium- and calmodulin-dependent protein kinase complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043197; C:dendritic spine; IDA:UniProtKB.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005516; F:calmodulin binding; IPI:BHF-UCL.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; IBA:GO_Central.
DR   GO; GO:0035254; F:glutamate receptor binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0038166; P:angiotensin-activated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0060996; P:dendritic spine development; IMP:UniProtKB.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0051346; P:negative regulation of hydrolase activity; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1990443; P:peptidyl-threonine autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000124; P:regulation of endocannabinoid signaling pathway; ISS:UniProtKB.
DR   GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; ISS:ParkinsonsUK-UCL.
DR   GO; GO:2001222; P:regulation of neuron migration; IMP:UniProtKB.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0046928; P:regulation of neurotransmitter secretion; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0002931; P:response to ischemia; ISS:ParkinsonsUK-UCL.
DR   InterPro; IPR013543; Ca/CaM-dep_prot_kinase-assoc.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR032710; NTF2-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF08332; CaMKII_AD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF54427; SSF54427; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calmodulin-binding;
KW   Cell projection; Disease variant; Intellectual disability; Kinase;
KW   Lipoprotein; Magnesium; Metal-binding; Nucleotide-binding; Palmitate;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Synapse; Transferase.
FT   CHAIN           1..478
FT                   /note="Calcium/calmodulin-dependent protein kinase type II
FT                   subunit alpha"
FT                   /id="PRO_0000086091"
FT   DOMAIN          13..271
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          290..300
FT                   /note="Calmodulin-binding"
FT   REGION          310..320
FT                   /note="Interaction with BAALC"
FT                   /evidence="ECO:0000250"
FT   REGION          314..341
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        322..341
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        135
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         19..27
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         42
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         13
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P11798"
FT   MOD_RES         257
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11275"
FT   MOD_RES         286
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P11275"
FT   MOD_RES         330
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11798"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11798"
FT   MOD_RES         333
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11798"
FT   MOD_RES         336
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P11798"
FT   MOD_RES         337
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P11798"
FT   MOD_RES         404
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11798"
FT   VAR_SEQ         328
FT                   /note="K -> KKRKSSSSVQLM (in isoform B)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_004766"
FT   VARIANT         98
FT                   /note="F -> S (in MRD53; no effect on protein abundance;
FT                   decreased autophosphorylation; decreased neuronal
FT                   migration; dbSNP:rs1554122526)"
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT                   /id="VAR_080579"
FT   VARIANT         109
FT                   /note="E -> D (in MRD53; no effect on protein abundance;
FT                   increased autophosphorylation; decreased neuronal
FT                   migration)"
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT                   /id="VAR_080580"
FT   VARIANT         112
FT                   /note="A -> V (in MRD53; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT                   /id="VAR_080581"
FT   VARIANT         138
FT                   /note="P -> A (in MRD53; unknown pathological significance;
FT                   no effect on protein abundance; no effect on
FT                   autophosphorylation; no effect on neuronal migration)"
FT                   /evidence="ECO:0000269|PubMed:25533962,
FT                   ECO:0000269|PubMed:29100089"
FT                   /id="VAR_080582"
FT   VARIANT         183
FT                   /note="E -> V (in MRD53; increased ubiquitin-mediated
FT                   proteasomal degradation with a dominant negative effect on
FT                   wild-type protein; decreased localization to dendritic
FT                   spines; no effect on holoenzyme assembly; loss of
FT                   interaction with SHANK3; loss of interaction with GRIN2B;
FT                   loss of interaction with CACNB2; loss of interaction with
FT                   LRRC7; loss of interaction with GRM5; decreased protein
FT                   serine/threonine kinase activity with a dominant negative
FT                   effect on wild-type protein; decreased autophosphorylation;
FT                   changed dendritic spine development; decreased neuronal
FT                   migration; dbSNP:rs1554122129)"
FT                   /evidence="ECO:0000269|PubMed:28130356,
FT                   ECO:0000269|PubMed:29100089"
FT                   /id="VAR_080583"
FT   VARIANT         212
FT                   /note="P -> L (in MRD53; unknown pathological significance;
FT                   no effect on protein abundance; no effect on
FT                   autophosphorylation; no effect on neuronal migration;
FT                   dbSNP:rs926027867)"
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT                   /id="VAR_080584"
FT   VARIANT         212
FT                   /note="P -> Q (in MRD53; increased basal
FT                   autophosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:29560374"
FT                   /id="VAR_081160"
FT   VARIANT         235
FT                   /note="P -> L (in MRD53; unknown pathological significance;
FT                   no effect on protein abundance; no effect on
FT                   autophosphorylation; no effect on neuronal migration;
FT                   dbSNP:rs864309606)"
FT                   /evidence="ECO:0000269|PubMed:29100089,
FT                   ECO:0000269|PubMed:29560374"
FT                   /id="VAR_080585"
FT   VARIANT         282
FT                   /note="H -> R (in MRD53; decreased protein abundance;
FT                   increased autophosphorylation; decreased neuronal
FT                   migration; dbSNP:rs1554121875)"
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT                   /id="VAR_080586"
FT   VARIANT         286
FT                   /note="T -> P (in MRD53; no effect on protein abundance;
FT                   loss of autophosphorylation; loss of neuronal migration;
FT                   dbSNP:rs1554121872)"
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT                   /id="VAR_080587"
FT   VARIANT         466
FT                   /note="H -> Y (in MRT63; decreased oligomerization;
FT                   dbSNP:rs1554119274)"
FT                   /evidence="ECO:0000269|PubMed:29784083"
FT                   /id="VAR_081161"
FT   MUTAGEN         42
FT                   /note="K->R: No effect on protein stability or degradation.
FT                   No effect on neuronal migration; when associated with
FT                   P-286."
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT   MUTAGEN         286
FT                   /note="T->A: No effect on neuronal migration."
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT   MUTAGEN         286
FT                   /note="T->D: Loss of neuronal migration."
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT   MUTAGEN         286
FT                   /note="T->P: No effect on neuronal migration; when
FT                   associated with R-42."
FT                   /evidence="ECO:0000269|PubMed:29100089"
FT   MUTAGEN         466..478
FT                   /note="Missing: Loss of oligomerization."
FT                   /evidence="ECO:0000269|PubMed:29784083"
FT   CONFLICT        365
FT                   /note="D -> G (in Ref. 1; AAD30558/AAD30559)"
FT                   /evidence="ECO:0000305"
FT   HELIX           8..12
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   STRAND          13..21
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   STRAND          26..32
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           33..35
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   STRAND          37..45
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           46..48
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           51..66
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   STRAND          75..81
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   STRAND          84..89
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           97..104
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           109..128
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           138..140
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   STRAND          141..144
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   STRAND          152..154
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           157..159
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           182..186
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           193..208
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           218..227
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           236..239
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           242..251
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   TURN            256..258
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           262..266
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           269..272
FT                   /evidence="ECO:0007829|PDB:6X5G"
FT   HELIX           274..277
FT                   /evidence="ECO:0007829|PDB:2VZ6"
FT   HELIX           284..298
FT                   /evidence="ECO:0007829|PDB:2VZ6"
FT   HELIX           347..362
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   HELIX           366..372
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   STRAND          373..380
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   HELIX           382..384
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   STRAND          388..392
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   HELIX           393..401
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   TURN            402..406
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   STRAND          410..422
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   TURN            423..425
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   STRAND          426..438
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   STRAND          440..442
FT                   /evidence="ECO:0007829|PDB:5IG3"
FT   STRAND          444..458
FT                   /evidence="ECO:0007829|PDB:6OF8"
FT   STRAND          461..471
FT                   /evidence="ECO:0007829|PDB:6OF8"
SQ   SEQUENCE   478 AA;  54088 MW;  208143A311BA9262 CRC64;
     MATITCTRFT EEYQLFEELG KGAFSVVRRC VKVLAGQEYA AKIINTKKLS ARDHQKLERE
     ARICRLLKHP NIVRLHDSIS EEGHHYLIFD LVTGGELFED IVAREYYSEA DASHCIQQIL
     EAVLHCHQMG VVHRDLKPEN LLLASKLKGA AVKLADFGLA IEVEGEQQAW FGFAGTPGYL
     SPEVLRKDPY GKPVDLWACG VILYILLVGY PPFWDEDQHR LYQQIKAGAY DFPSPEWDTV
     TPEAKDLINK MLTINPSKRI TAAEALKHPW ISHRSTVASC MHRQETVDCL KKFNARRKLK
     GAILTTMLAT RNFSGGKSGG NKKSDGVKES SESTNTTIED EDTKVRKQEI IKVTEQLIEA
     ISNGDFESYT KMCDPGMTAF EPEALGNLVE GLDFHRFYFE NLWSRNSKPV HTTILNPHIH
     LMGDESACIA YIRITQYLDA GGIPRTAQSE ETRVWHRRDG KWQIVHFHRS GAPSVLPH
//
